Fetus Receives Life-Saving Medication Inside Womb in Medical First
Instead of giving medicine to a child with severe neuromuscular complications after they are born, a new case study details how a prospective mother agreed to take the medicine for her developing fetus while she was still pregnant.
A prenatal test had shown that her fetus held two genetic mutations indicating type 1 spinal muscular atrophy (SMA), which usually results in severe muscle weakness and breathing difficulties within six months of birth.
Historically, most children with type 1 SMA die by their second birthday, usually from respiratory failure. However, the child in this study has so far made it to the age of two and a half years with no sign of symptoms.
The parents of the treated child had previously experienced the loss of their baby to spinal muscular atrophy, and when testing showed their most recent fetus also had the progressive neuromuscular disease, they wanted to know if they could start treatments earlier.
For this single case, the FDA approved the early administration of the oral drug risdiplam, brand name Evrysdi, owned by the pharmaceutical company F. Hoffmann-La Roche AG.
Over the years, randomized controlled trials have shown risdiplam to be both safe and effective at treating spinal muscular atrophy in newborns, and the younger the kids are when they start receiving the medicine, the better the outcomes overall.
In the new study, the pregnant mother took a dose of risdiplam each day for six weeks before giving birth. Testing found that the medicine trickled right through her umbilical cord blood and the amniotic fluid bathing her fetus. After birth, it was the infant that was given the daily oral drug, not the mother.
Pediatric neurologist Michelle Farrar, who is working on a minimally invasive gene therapy treatment for SMA in Australia, told Smriti Mallapaty at Nature that the baby girl with SMA "has been effectively treated, with no manifestations of the condition" even 30 months after birth.
In 2020, risdiplam was first approved by the US Food and Drug Administration (FDA) for kids with spinal muscular atrophy, but only over the age of two months.
Recent clinical trials funded by Roche, however, found the majority of children with spinal muscular atrophy treated with risdiplam before six weeks of age could swallow, feed, sit, stand, and walk on their own after two years of treatment. None required permanent ventilation.
Risdiplam works to prevent the degeneration of nerve cells in the brain and body by increasing the concentration of a crucial protein, called survival motor neuron (SMN) protein. Active SMN proteins are lacking in those with genetic mutations that cause spinal muscular atrophy.
"In children with SMA, motor neuron degeneration starts before the onset of symptoms, so time is of the essence if we hope to preserve muscle function," said pediatric neurologist Laurent Servais in a press release for a Roche clinical trial in 2024.
"It's heartening to see that through early intervention with Evrysdi these children have achieved important milestones like sitting, standing, and walking that would typically be unattainable without treatment."
Whether or not the recent case study in the US will inspire and embolden doctors and parents to trial risdiplam at earlier stages of development remains to be seen.
"Results in this single case cannot be generalized but may support the consideration of prenatal risdiplam treatment for SMA identified in utero," write the authors of the correspondence.
The study was published in The New England Journal of Medicine.
There's a Critical Thing We Can All Do to Keep Alzheimer's Symptoms at Bay
Traces of a Nutrient in Brazil Nuts Could Fight Cancer, But Dosage Is Crucial
Tardigrade Protein Could Soon Make Cancer Patients More Radiation Proof
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
28 minutes ago
- Time Magazine
FDA Warns Public Not to Eat Potentially Radioactive Shrimp
The Food and Drug Administration has warned the public not to consume certain frozen shrimp products sold at Walmart due to possible contamination with Cesium-137, a radioactive isotope. It said the warning affects the Great Value brand of raw frozen shrimp sold at the superstore, adding that anyone who purchased the product should dispose of it. A statement from the agency said the FDA was 'actively investigating reports of Cesium-137 (Cs-137) contamination in shipping containers and frozen shrimp products' in a shipment from Indonesia. It said that the U.S. Customs & Border Protection (CBP) had detected Cs-137 in shipping containers at four U.S. ports: Los Angeles, Houston, Savannah, and Miami. The FDA added that although it had not confirmed the presence of contamination in any commercial product in the United States, the shrimp products appear 'to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern.' 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away. Do not eat or serve this product,' the FDA statement added. The FDA said limited exposure to Cs-137 can cause 'an elevated risk of cancer, resulting from damage to DNA within living cells of the body.' The FDA has recommended that Walmart recall this product. TIME has contacted Walmart for a response. This is a developing story.
Forbes
28 minutes ago
- Forbes
FDA Suggest Walmart Recalls Frozen Shrimp After Radiation Detected At Port
The Food and Drug Administration is warning that some Great Value brand frozen shrimp sold at Walmart could be contaminated with radioactive isotope Cesium-137 after Customs and Border Protection detected the substance in shipping containers at four major American ports and at least one sample of shrimp. Cesium-137 was detected in some frozen shrimp coming from Indonesia—but none that have been sold in stores yet. getty The FDA is investigating the potential contamination and has not 'confirmed the presence of contamination in any product in commerce,' they are still warning consumers to avoid eating shrimp that come from the same Indonesian producer BMS Foods. The FDA is recommending Walmart recall frozen shrimp coming from BMS Foods, and the retailer has not returned a request for comment from Forbes. This is a breaking story and will be updated.
CBS News
28 minutes ago
- CBS News
Walmart's Great Value shrimp has risk of radioactive contamination, FDA says
Some frozen shrimp sold at Walmart under the Great Value label are at risk of radioactive contamination and shouldn't be consumed, according to a warning from the U.S. Food and Drug Administration. The frozen shrimp were imported from Indonesian company PT. Bahari Makmur Sejati and sold at Walmart stores as Great Value brand frozen raw shrimp, the FDA said on Tuesday. The agency noted it has recommended that Walmart recall the product. Walmart didn't immediately respond to a request for comment. The shrimp could be contaminated with a radioactive isotope called Cesium-137, although the FDA said that no products as of yet have tested positive for it. The agency said it issued the warning about Walmart's Great Value shrimp after it had detected Cesium-137 in a single shipment of frozen shrimp from PT. Bahari Makmur Sejati. That shipment "did not enter U.S. commerce," the FDA said. Here's what to know about the warning. The FDA said that consumers "should not eat or serve certain lots of Great Value raw frozen shrimp from Walmart." The lots are: Consumers who bought the shrimp cited in the FDA's notice should throw it away, the agency said. "Distributors and retailers should dispose of this product and should not sell or serve this product," the FDA added. Cesium-137, or Cs-137, is the radioactive form of the element cesium, according to the U.S. Environmental Protection Agency. Produced by nuclear fission, it's used in medical devices and is also a byproduct of nuclear fission in nuclear reactors and weapons testing, the EPA notes. The Cesium-137 detected in the imported shrimp was about 68 Bq/kg, which the FDA said sits below its threshold of 1200 Bq/kg for "levels of concern" for imported foods. "At this level, the product would not pose an acute hazard to consumers," the FDA said in its warning notice. However, the FDA noted that repeated low-dose exposure to Cesium-137 carries an "elevated risk of cancer, resulting from damage to DNA within living cells of the body." It added, "Avoiding products like the shipment FDA tested with similar levels of Cs-137 is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time."
